EMA Confirms Rejection of Neurodegenerative Disease Drugs

Views: 2670

The European Medicines Agency (EMA) has upheld an earlier recommendation to deny marketing authorization for Masitinib AB Science (masitinib), an oral treatment for amyotrophic lateral sclerosis (ALS).  In a meeting on October 17, the EMA’s Committee for Medicinal Products for Human Use (CHMP) reaffirmed its concerns about the reliability of the data supporting the drug…
Read More